Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : RNDP-001
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Alaska Permanent Fund Corporation
Deal Size : $82.0 million
Deal Type : Series A Financing
Kenai Therapeutics Secures $82 Million for Allogeneic Cell Therapies
Details : The financed proceeds will support clinical development of RNDP-001, an iPSC-derived, allogeneic dopamine progenitor cell therapy for Parkinson’s disease, currently in preclinical studies.
Product Name : RNDP-001
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
February 29, 2024
Lead Product(s) : RNDP-001
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Alaska Permanent Fund Corporation
Deal Size : $82.0 million
Deal Type : Series A Financing
Reset All
